Biotechnology firm Alector has announced initial positive results from the Phase I/Ib INFRONT clinical trial of AL001 to treat frontotemporal dementia patients with a granulin mutation (FTD-GRN).
A loss of function mutation in the progranulin gene is known to be one of the primary drivers of FTD, a progressive and severe form of dementia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The ongoing Phase I/Ib trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously AL001 in healthy volunteers and subjects with FTD-GRN.
It involves single and multiple AL001 doses and will measure the plasma and cerebrospinal fluid (CSF) levels of progranulin, a disease-specific biomarker.
Results from 50 healthy volunteers and four patients showed AL001 to be generally safe and well-tolerated up to the highest dose level.
In addition, the drug candidate led to a dose-dependent rise in PGRN levels in plasma, as well as CSF of healthy volunteers and also FTD-GRN patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt was observed that AL001 led to a three-fold increase in plasma PGRN and doubled the level in the CSF of asymptomatic and symptomatic FTD-GRN patients, restoring it to the normal range.
Alector chief medical officer Robert Paul said: “Our initial findings in this study show that treatment with AL001 is able to restore the level of progranulin in FTD-GRN patients back to the normal range.
“The good tolerability and safety observed, and promising progranulin response in the first four patients, support advancing AL001 to a Phase II study in the second half of this year for the treatment of FTD-GRN patients.”
The trial is expected to be completed in December.
